MSB Trading - 2020, page-1473

A large majority of analysts have never worked in the Medical profession, either as doctors, scientists or researchers. In other words, individually they know less about the way MSB works then the collective talent of the MSB regulars.

Analysts collect data on current drugs and market sizes then plug those numbers into excel spreadsheet along with their own assumptions to come out with a valuation that's then risk adjusted and then discounted for risk. Final they put a disclaimer at the bottom of the valuation that basically says, "We Guessed and have no idea what the SP will be when the treatment is commercialised", buy at your own risk.

What's interesting is most Analysts and investor are solely focused on the FDA/USA market. MSB's market isn't limited to the USA, although I do understand it's a large part of the medical market.

My question to the collective, if the FDA reject the use of MSB's treatments in the USA can MSB provide the treatment to USA citizens in an external country that has previously approved the use of MSB's treatments?